Dall'Aglio E, Reaven G M, Azhar S
Endocrinology. 1986 Jan;118(1):108-11. doi: 10.1210/endo-118-1-108.
The level of fructose 2,6-bisphosphate (F2,6P2), a potent stimulator of 6-phosphofructo-1-kinase and inhibitor of fructose 1,6-bisphosphatase, was measured in three different muscle types (tensor fascia latae, biceps femoris, and soleus) and in the liver of normal and diabetic rats. The mean (+/- SEM) content of F2,6P2 (nanomoles per g tissue) varied among the three types of skeletal muscle in normal rats, with the biceps femoris having the highest (0.97 +/- 0.15) and the soleus the lowest (0.57 +/- 0.03) levels. However, these differences were unrelated to simultaneous estimates of skeletal muscle activity of 6-phosphofructo-1-kinase activity. The total concentration of F2,6P2 was more than 8-fold higher (8.5 +/- 0.9) in the liver, and this value fell to 5.3 +/- 0.8 (P less than 0.05) after the induction of diabetes with streptozotocin. In contrast, F2,6P2 levels did not fall in skeletal muscle of rats with streptozotocin-induced diabetes, and the concentration actually increased. Thus, the fall in hepatic F2,6P2 concentration associated with insulin deficiency was not observed in skeletal muscle.
在正常大鼠和糖尿病大鼠的三种不同肌肉类型（阔筋膜张肌、股二头肌和比目鱼肌）以及肝脏中，检测了果糖2,6 - 二磷酸（F2,6P2）的水平。F2,6P2是6 - 磷酸果糖 - 1 - 激酶的强效刺激剂和果糖1,6 - 二磷酸酶的抑制剂。在正常大鼠中，三种骨骼肌类型的F2,6P2平均含量（±标准误，每克组织的纳摩尔数）有所不同，股二头肌的含量最高（0.97±0.15），比目鱼肌的含量最低（0.57±0.03）。然而，这些差异与同时对6 - 磷酸果糖 - 1 - 激酶活性的骨骼肌活性估计无关。肝脏中F2,6P2的总浓度高出8倍多（8.5±0.9），在用链脲佐菌素诱导糖尿病后，该值降至5.3±0.8（P＜0.05）。相反，链脲佐菌素诱导的糖尿病大鼠的骨骼肌中F2,6P2水平并未下降，实际上浓度还增加了。因此，在骨骼肌中未观察到与胰岛素缺乏相关的肝脏F2,6P2浓度下降。
